Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $70.00M |
| Net Income (Most Recent Fiscal Year) | $22.37M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.87 |
| Pre-Tax Margin (Trailing 12 Months) | 31.95% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -32.10% |
| Return on Assets (Trailing 12 Months) | -25.21% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.67 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $0.52 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.45M |
| Free Float | 52.12M |
| Market Capitalization | $117.21M |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 3.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.29% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.47% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |